Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Smith & Nephew plc SNN
$31.61
-$0.2 (-0.64%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
13912816470.00000000
-
week52high
33.09
-
week52low
21.78
-
Revenue
5215000000
-
P/E TTM
64
-
Beta
0.34541900
-
EPS
0.51000000
-
Last Dividend
0.75000000
-
Next Earnings Date
28 февр 2023 г. в 05:00
Описание компании
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Redburn Partners | Neutral | Sell | 04 мар 2022 г. |
| Canaccord Genuity | Buy | Buy | 30 апр 2021 г. |
| Bernstein | Outperform | Market Perform | 18 дек 2020 г. |
| Canaccord Genuity | Buy | Buy | 30 окт 2020 г. |
| CFRA | Hold | Hold | 07 мая 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Smith & Nephew holds guidance as revenue rises 3.8%
Proactive Investors
26 апр 2023 г. в 02:38
Smith & Nephew PLC (LSE:SN) held full-year guidance as it reported strong growth in its Sports Medicine and Advanced Wound Management businesses had underpinned an improvement in first quarter revenue. The Watford-based medical equipment manufacturing company said revenue in the quarter to March 31 rose 3.8% on a reported basis to US$1.36 billion from US$1.31 billion or 6.9% on an underlying basis.
Smith & Nephew shares worth 'buying' up £16, says leading bank
Proactive Investors
17 апр 2023 г. в 09:11
RBC Capital said expects Smith & Nephew PLC (LSE:SN) to post revenue growth of 3.9% in the first quarter, as the company benefits from positive trends in US elective procedures while facing headwinds in China. In a note to clients, the Canadian bank maintained an "outperform" rating and a £16 price target for the London-listed med-tech giant.
3 Healthcare Dividend Payers With Big Price Growth
MarketBeat
14 апр 2023 г. в 07:11
You don't see financial TV channels dedicated to minute-by-minute coverage of dividend yield or increases, but for investors in companies like Sanofi (NASDAQ: SNY), AstraZeneca plc (NASDAQ: AZN), and Smith & Nephew plc (NYSE: SNN), there should be at least a little excitement about intrinsically boosting your stock's return every quarter.
Smith & Nephew's (SNN) CIT Technology Favored by New Study
Zacks Investment Research
24 мар 2023 г. в 09:12
Smith & Nephew (SNN) achieves a positive response for its COBLATION-Technology-infused Intracapsular Tonsillectomy Technique, providing fast patient recovery over existing surgeries.
Smith & Nephew (SNN) Simplifies ACL Surgery With New Offers
Zacks Investment Research
09 мар 2023 г. в 09:11
Smith & Nephew (SNN) introduces QUADTRAC System and broadens ULTRABUTTON Adjustable Fixation Devices portfolio for ACL reconstruction.